<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619863</url>
  </required_header>
  <id_info>
    <org_study_id>ATHN 7</org_study_id>
    <nct_id>NCT03619863</nct_id>
  </id_info>
  <brief_title>ATHN 7: Hemophilia Natural History Study</brief_title>
  <acronym>ATHN 7</acronym>
  <official_title>A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Thrombosis and Hemostasis Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Thrombosis and Hemostasis Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a real-world study of the safety of the treatments used for people with hemophilia.
      The study will follow people with hemophilia A or B from across the country for about 4 years
      as they receive treatment. The hemophilia treatment center (HTC) physician and participant
      will decide on the FDA-approved treatment to be used which may include non-factor products,
      bypassing agents, or clotting factor replacement products. The goal of this research is to
      study the use of hemophilia treatment products and their outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional, minimal risk cohort study will enroll and follow patients with
      hemophilia A or B as they receive hemophilia treatment for 4 years. This is a pragmatic study
      of real-world practices across a wide range of patients which will be ongoing as new
      treatment products receive FDA approval and will be advantageous to the entire hemophilia
      community. The total study duration is planned for 6 years.

      The patients are seen at baseline, annually, and at study exit. Patients will also receive
      routine quarterly follow-up phone calls from HTC staff to review medical history, bleed
      events, and product treatment history. Other visits for unplanned events or for the change of
      treatment product will be scheduled as necessary. All required study visits will be planned
      to coincide with routine clinical care whenever possible. Co-enrollment in the ATHNdataset by
      patients is required to participate in the study.

      Please note - the treatment regimen will be at the discretion of the patients' hemophilia
      caregivers. No treatment products are being provided by the study nor will the participants
      be paid. However, inhibitor titer testing will be provided at no cost to patients by the
      Center for Disease Control and Prevention (CDC).

      The primary objective is to determine the safety of non-factor products, bypassing agents or
      clotting factor replacement products when used for people with hemophilia with or without
      inhibitors. Safety will be measured by those events listed in the European Haemophilia Safety
      Surveillance (EUHASS).

      Data collected will include eligibility, demographics, medical history, hemophilia history
      (genotype and family history), inhibitor history and immune tolerance induction (ITI)
      treatment regimen (if applicable), co-morbidities at baseline (i.e., HIV, Hepatitis C),
      detailed treatment product(s) usage, bleeding events, surgical procedures, and EUHASS adverse
      events and other adverse events of special interest. Data collection will also include
      patient-reported outcome questionnaires regarding health-related quality of life, treatment
      use and patient perceptions of treatment products.

      Sub-studies

      A number of sub-studies are planned with pharmaceutical sponsors to collect information from
      patients about their specific product use. Participation in these sub-studies (Product
      Specific Modules) is optional and sub-study visits will be planned to coincide with HTC
      visits. The modules will collect information from patients about their perception and use of
      treatment products, physical activity levels and other general health questions. This data
      will be collected via questionnaire.

      Data Collection System

      All data collected will be entered into electronic case report forms (eCRFs) within the
      secure ATHN System by HTC site personnel. All participating study sites will have in place a
      current, executed Data Use and Business Associate Agreement (DUBAA) with ATHN.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Safety of treatment products used for hemophilia care will be assessed based on the number of reportable European Haemophilia Safety Surveillance (EUHASS) events documented on the ATHN Adverse Event Module Form.</measure>
    <time_frame>6 years</time_frame>
    <description>All treatment-related reportable adverse events will be documented on the ATHN Adverse Event Module Form based on EUHASS reportable events which include: death, factor inhibitor development, venous thrombosis, allergic reactions, treatment-emergent side effects, new malignancies, cardiovascular events, and blood-borne infections. Other treatment-related events to be documented on the ATHN Adverse Event Module Form including thrombotic microangiopathies, injection site reactions, drug-induced liver injury and anti-drug antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of non-factor products, bypassing agents and clotting factor replacement products will be evaluated based on the participant's number of bleeding events reported as the annualized bleeding rate (ABR).</measure>
    <time_frame>6 years</time_frame>
    <description>Annualized bleeding rates (bleeds/year) are calculated as the number of bleeding events divided by length of time of the treatment regimen, in years. Participants will report bleeding including spontaneous bleeding, traumatic bleeding, joint related and non-joint bleeding during routine quarterly follow-up with hemophilia care providers. Participants will also have blood loss associated with surgical procedures documented through medical chart review as noted by the surgical care providers. All bleeding data will be gathered and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing regimens for hemophilia treatment products and total amount utilized by the study participant for prophylaxis and treatment of bleeds will be assessed.</measure>
    <time_frame>6 years</time_frame>
    <description>The routine quarterly contact by hemophilia care providers with study participants will be used to evaluate their treatment use and will document dosing regimens of hemophilia treatment products, amount of product used, number of participants switching to a different product, number of participants switching between factor and non-factor products, and/or number of participants staying on the current treatment product and the reason for their choice of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target joint monitoring</measure>
    <time_frame>6 years</time_frame>
    <description>The number and location of target joints at study entry, incidence of target joint development while on study, and the number of target joints that resolve following study enrollment will be documented and analyzed.
The number and location of target joints at study entry, incidence of target joint development while on study, and the number of target joints that resolve following study enrollment will be documented and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment is rated by health-related outcomes tools: EQ-5D-5L, Patient-Reported Outcomes Measurement Information System (PROMIS), Global Adherence Rating (GAR), and Treatment Satisfaction with Medicines Questionnaire (SATMED-Q).</measure>
    <time_frame>6 years</time_frame>
    <description>EuroQol Group's EQ-5D-5L assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Opinions in the 5 categories can be stated as a health profile or converted to a single summary index number. Opinion on overall health is on a scale of 0 to 100 with 100 as best health imagined. PROMIS Profile 29 (adults)/ 25 (peds)/ Parent Proxy 25 assess physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles/activities, and pain. Questions are ranked on a 5-point Likert Scale and one question on pain has a 11-point rating scale. GAR assesses adherence to the prescribed regimen on a scale of 0 to 10 with 10 always taken as prescribed. SATMED-Q assesses the satisfaction with the prescribed treatment based on a Likert scale and provides a total score for treatment satisfaction by summing all domains: side effects, efficacy, convenience and ease of use, impact of the medicine, medical follow-up/review and overall opinion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Real world effectiveness of treatment products assessed by the healthcare providers as measure by the number and types of medical visits and/or hospitalizations per year.</measure>
    <time_frame>6 years</time_frame>
    <description>Healthcare providers will document the number and types of medical visits/hospitalization per year that are related to hemophilia care and treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <condition>Haemophilia A Without Inhibitor</condition>
  <condition>Hemophilia B With Inhibitor</condition>
  <condition>Haemophilia B Without Inhibitor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll approximately 280 patients with hemophilia who meet the eligibility
        criteria and receiving care from one of the ATHN-affiliated Hemophilia Treatment Centers
        (HTC).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Congenital hemophilia A or B of any severity with or without inhibitors receiving a
             current therapy, a non-factor product, or for whom use of a non-factor product is a
             possibility;

          2. Able to give informed consent (by patient or parent/authorized guardian); and

          3. Co-enrollment in the ATHNdataset.

        Exclusion Criteria:

          1. Presence of any known bleeding disorder other than congenital hemophilia A or B;

          2. Presence of concurrent hemophilia and a second hemostatic defect (low Von Willebrand
             Factor (VWF) without Von Willebrand disease (VWD) diagnosis is not excluded); and

          3. Unable or unwilling to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyler Buckner, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hemophilia and Thrombosis Center/ University of Colorado Anschutz Medical Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Recht, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hemophilia Center at Oregon Health &amp; Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Fedor, ND, RN, CCRC</last_name>
    <phone>800-360-2846</phone>
    <email>cfedor@athn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki Hirsh, MS, CCRC</last_name>
    <email>nhirsh@athn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Hemophilia and Thrombosis Center at Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erica Olson</last_name>
      <email>eolson1@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Christine Knoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopedic Institute for Children Hemophilia Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Chang, NP</last_name>
      <email>ChristopherChan@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Doris Quon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCD Hemostasis and Thrombosis Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Schafer</last_name>
      <email>klschafer@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Ducore, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacquie Limjoco</last_name>
      <email>jlimjoco@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Courtney Thornburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Pediatric Hemophilia Treatment Center at Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Vanderpoel</last_name>
      <email>victoria.vanderpoel@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Tiffany Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hemophilia and Thrombosis Center/ University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Smith</last_name>
      <phone>303-724-5700</phone>
      <email>julie.smith@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Furton</last_name>
      <email>lindsey.furton@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tyler Buckner, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Guelcher, RN</last_name>
      <phone>202-476-3622</phone>
      <email>cguelche@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Kassandra Lopez</last_name>
      <email>klopez2@childrensnational.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Guerrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Hemophilia Treatment Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Mercado</last_name>
      <email>rebeccahmercado@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Tung Wynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allan Ciciriello</last_name>
      <email>mailto:allan.ciciriello@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Bobby Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josephine Volgi</last_name>
      <email>Josephine_R_Volgi@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brian Jenkins</last_name>
      <email>Brian_H_Jenkins@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mindy Simpson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center (IHTC)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kourtney Brougher</last_name>
      <email>kbrougher@ihtc.org</email>
    </contact>
    <investigator>
      <last_name>Amy Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Regional Hemophilia Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lois Hester</last_name>
      <email>lhester@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Shannon Carpenter, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melody Benton</last_name>
      <phone>504-988-3596</phone>
      <email>mbenton@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Tamuella Singleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Hemophilia and Thrombosis Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celeste Prescott</last_name>
      <phone>207-396-7312</phone>
      <email>c.prescott@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Eric Larsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Hemophilia Center at Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tien Hua</last_name>
      <phone>617-919-6407</phone>
      <email>Tien.Hua@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Stacy Croteau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hemophilia and Coagulation Disorders Program</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Hauker</last_name>
      <phone>734-936-5905</phone>
      <email>rhauke@umich.med.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Pipe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan Hemostasis and Thrombosis Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bryan Hannan</last_name>
      <email>bhannan@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Meera Chitlur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Anderson, LPN</last_name>
      <phone>517-353-9385</phone>
      <email>kathleen.anderson@hc.msu.edu</email>
    </contact>
    <investigator>
      <last_name>Roshni Kulkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The John Bouhasin Center for Children with Bleeding Disorders</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Allred</last_name>
      <email>katherine.allred@health.slu.edu</email>
    </contact>
    <investigator>
      <last_name>John Puetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hemostasis and Thrombosis Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89178</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becki Berkowitz</last_name>
      <email>becki.berkowitz@htcnv.org</email>
    </contact>
    <investigator>
      <last_name>Amber Federizo, NP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phyllis Kandl</last_name>
      <email>Phyllis.Kandl@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Alice Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ted R Montoya Hemophilia Program</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Archuleta</last_name>
      <email>DAArchuleta@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Shirley Abraham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center Comprehensive Hemophilia Center</name>
      <address>
        <city>Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Stanco</last_name>
      <email>jstanco@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Suchitra Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilene Goldberg</last_name>
      <phone>212-746-3403</phone>
      <email>igoldber@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine McGuinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Affiliate Clinic at Novant Hemby Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Lineberger</last_name>
      <email>emlineberger@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Paulette Bryant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Science</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Blackwell</last_name>
      <email>rablackw@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Natalia Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center Hemophilia Treatment Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alyssa Amato</last_name>
      <email>amatoal@mail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Palascak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erica Godsey</last_name>
      <email>erica.godsey@promedica.org</email>
    </contact>
    <investigator>
      <last_name>Dagmar Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Lattimore, RN</last_name>
      <phone>503-418-4495</phone>
      <email>lattimor@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Recht, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia (CHOP)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Britton</last_name>
      <email>brittonj@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Raffini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Panercki</last_name>
      <phone>215-614-0506</phone>
      <email>Karen.Panckeri@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Cuker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hemophilia Center of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Kadosh, RN</last_name>
      <phone>412-209-7288</phone>
      <email>jkadosh@itxm.org</email>
    </contact>
    <investigator>
      <last_name>Margaret Ragni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saheed Amuda</last_name>
      <email>Saheed.Amuda@STJUDE.ORG</email>
    </contact>
    <investigator>
      <last_name>Ulrike Reiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee - Hemophilia Clinic of Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Osha Smith-Payne</last_name>
      <email>osha.smith-payne@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Sandeep Rajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Worth Bleeding Disorders Program</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Di Marcos Pereira</last_name>
      <email>DiMarcos.Pereira@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Timothy McCavit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulf States Hemophilia and Thrombosis Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krishna Cannon</last_name>
      <email>Krishna.Cannon@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Miguel Escobar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Center for Bleeding Disorders Bloodworks Northwest d/b/a Puget Sound Blood Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Ruska</last_name>
      <phone>206-689-6539</phone>
      <email>sarahru@psbc.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca Kruse-Jarres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Konkle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Stephany</last_name>
      <phone>414-257-2424</phone>
      <email>karen.stephany@bcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Lemancyzk</last_name>
      <phone>414 257 2424</phone>
      <email>megan.lemancyzk@bcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lynn Malec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/ncbddd/hemophilia/data.html</url>
    <description>Centers for Disease Control accessed</description>
  </link>
  <reference>
    <citation>Ragni MV. Targeting Antithrombin to Treat Hemophilia. N Engl J Med. 2015 Jul 23;373(4):389-91. doi: 10.1056/NEJMcibr1505657.</citation>
    <PMID>26200986</PMID>
  </reference>
  <reference>
    <citation>Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.</citation>
    <PMID>23553768</PMID>
  </reference>
  <reference>
    <citation>Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769.</citation>
    <PMID>27223146</PMID>
  </reference>
  <reference>
    <citation>Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.</citation>
    <PMID>28691557</PMID>
  </reference>
  <reference>
    <citation>Carr ME, Tortella BJ. Emerging and future therapies for hemophilia. J Blood Med. 2015 Sep 3;6:245-55. doi: 10.2147/JBM.S42669. eCollection 2015. Review.</citation>
    <PMID>26366108</PMID>
  </reference>
  <reference>
    <citation>Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, Prabhala H, Zhang X, Attarwala H, Hutabarat R, Foster D, Milstein S, Charisse K, Kuchimanchi S, Maier MA, Nechev L, Kandasamy P, Kel'in AV, Nair JK, Rajeev KG, Manoharan M, Meyers R, Sorensen B, Simon AR, Dargaud Y, Negrier C, Camire RM, Akinc A. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015 May;21(5):492-7. doi: 10.1038/nm.3847. Epub 2015 Apr 13.</citation>
    <PMID>25849132</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>Non-Factor Products</keyword>
  <keyword>Bypassing Agents</keyword>
  <keyword>Clotting Factor Replacement Products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

